Year All2026202520242023202220212020 Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results March 12, 2026 Read More Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer March 9, 2026 Read More Lyell Immunopharma Announces Participation in March Investor Conferences February 23, 2026 Read More Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma February 12, 2026 Read More
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results March 12, 2026 Read More
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer March 9, 2026 Read More
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma February 12, 2026 Read More